

LIST OF CONTENTS

NUMBER 1

News	1
Editorial	
The strength of European oncology <i>J.F. Smyth</i>	6
Editorial Comment	
Recommended changes to oncology clinical trial design: Revolution or evolution? <i>M.J. Ratain, R.W. Humphrey, G.B. Gordon, G. Fyfe, P.C. Adamson, T.R. Fleming, W.M. Stadler, D.A. Berry and C.C. Peck</i>	8
Short Communications	
The effect of solar UVB doses and vitamin D production, skin cancer action spectra, and smoking in explaining links between skin cancers and solid tumours <i>W.B. Grant</i>	12
Protective effect from solar exposure, risk of an ecological fallacy <i>T.K. Grimsrud and A. Andersen</i>	16
Position Papers	
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) <i>C.M. Booth, A.H. Calvert, G. Giaccone, M.W. Lobbzoo, L.K. Seymour and E.A. Eisenhauer, On behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies</i>	19
Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) <i>C.M. Booth, A.H. Calvert, G. Giaccone, M.W. Lobbzoo, E.A. Eisenhauer and L.K. Seymour, On behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies</i>	25
Reviews	
Tamoxifen: Catalyst for the change to targeted therapy <i>V.C. Jordan</i>	30
How to assess anti-tumour efficacy by imaging techniques <i>S.J. Gwyther and L.H. Schwartz</i>	39
Mesothelin targeted cancer immunotherapy <i>R. Hassan and M. Ho</i>	46
Clinical Oncology	
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer <i>M.K. Kim, K.-J. Cho, G.Y. Kwon, S.-I. Park, Y.H. Kim, J.H. Kim, H.-Y. Song, J.H. Shin, H.Y. Jung, G.H. Lee, K.D. Choi and S.-B. Kim</i>	54
Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients <i>B. Quinn, C.M.J. Potting, R. Stone, N.M.A. Blijlevens, M. Flidner, A. Margulies and L. Sharp, a joint taskforce on behalf of the European Group for Blood and Marrow Transplantation (EBMT) and the European Oncology Nursing Society (EONS)</i>	61

Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes E.A. Rakha, M.E. El-Sayed, D.G. Powe, A.R. Green, H. Habashy, M.J. Grainge, J.F.R. Robertson, R. Blamey, J. Gee, R.I. Nicholson, A.H.S. Lee and I.O. Ellis	73
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics A. Awada, F. Cardoso, C. Fontaine, L. Dirix, J. De Grève, C. Sotiriou, J. Steinseifer, C. Wouters, C. Tanaka, U. Zoellner, P. Tang and M. Piccart	84
Paediatric Oncology	
Atopic dysfunction and risk of central nervous system tumours in children N.J. Harding, J.M. Birch, S.J. Hepworth and P.A. McKinney, on behalf of the UKCCS investigators	92
Epidemiology and Cancer Prevention	
Morbidity and mortality in relation to smoking among women and men of Chinese ethnicity: The Singapore Chinese Health Study A. Shankar, J.-M. Yuan, W.-P. Koh, H.-P. Lee and M.C. Yu	100
Common variants of DNA repair genes and malignant melanoma T. Dębniak, R.J. Scott, B. Górski, C. Cybulski, T. van de Wetering, P. Serrano-Fernandez, T. Huzarski, T. Byrski, L. Nagay, B. Dębniak, E. Kowalska, A. Jakubowska, J. Gronwald, D. Wokolorczyk, R. Maleszka, J. Kładny and J. Lubinski	110
Cancer prevalence in France: Time trend, situation in 2002 and extrapolation to 2012 M. Colonna, A. Danzon, P. Delafosse, N. Mitton, S. Bara, A.-M. Bouvier, O. Ganry, A.-V. Guizard, G. Launoy, F. Molinie, E.-A. Sauleau, C. Schwartz, M. Velten, P. Grosclaude and B. Tretarre	115
Thymic epithelial tumours: A population-based study of the incidence, diagnostic procedures and therapy W.K. de Jong, J.L.G. Blaauwgeers, M. Schaapveld, W. Timens, T.J. Klinkenberg and H.J.M. Groen	123
Experimental Oncology	
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer M. Marabese, S. Marchini, E. Marrazzo, P. Mariani, D. Cattaneo, R. Fossati, A. Compagnoni, M. Signorelli, U.M. Moll, A.M. Codegoni and M. Broggin	131
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF- β kinase antagonist, in mice L. Bueno, D.P. de Alwis, C. Pitou, J. Yingling, M. Lahn, S. Glatt and I.F. Trocóniz	142
Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines A. Pierce, N. Barron, R. Linehan, E. Ryan, L. O'Driscoll, C. Daly and M. Clynes	151
The α_1 -adrenergic receptor antagonist doxazosin inhibits EGFR and NF- κ B signalling to induce breast cancer cell apoptosis H. Hui, M.A. Fernando and A.P. Heaney	160
Calendar of Forthcoming Meetings	I
NUMBER 2	
News	167
Editorial Comment	
The multifaceted value of antidepressants in cancer therapeutics J. Lieb	172

Current Perspective

- The pathogenesis of cancer related fatigue: Could increased activity of pro-inflammatory cytokines be the common denominator? 175
A. Jager, S. Sleijfer and C.C.D. van der Rijt

Position Paper

- Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group 182
E. Van Cutsem, C. Van de Velde, A. Roth, F. Lordick, C.-H. Köhne, S. Cascinu and M. Aapro

Reviews

- Long-term survivors of adult cancers and uptake of primary health services: A systematic review 195
N.F. Khan, A. Ward, E. Watson, J. Austoker and P.W. Rose
- Childhood cancer survival in France, 1990–1999 205
E. Desandes, C. Berger, I. Tron, F. Demeocq, S. Bellec, P. Blouin, L. Casagrande, L. De Lumley, F. Freycon, A. Goubin, E. Le Gall, D. Sommelet, B. Lacour and J. Clavel

Clinical oncology

- An evaluation of a preparation of *Mycobacterium vaccae* (SRL172) as an immunotherapeutic agent in renal cancer 216
P.M. Patel, S. Sim, D.O. O'Donnell, A. Protheroe, D. Beirne, A. Stanley, J.M. Tourani, D. Khayat, B. Hancock, P. Vasey, A. Dalglish, C. Johnston, R.E. Banks and P.J. Selby
- Successful immunotherapy with *Mycobacterium vaccae* in the treatment of adenocarcinoma of the lung 224
J.L. Stanford, C.A. Stanford, M.E.R. O'Brien and J.M. Grange
- The actual citation impact of European oncological research 228
C. López-Illescas, F. de Moya-Anegón and H.F. Moed
- Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: Evaluation of a prognostic score for survival after high-dose chemotherapy 237
C. Sammler, J. Beyer, C. Bokemeyer, J.T. Hartmann and O. Rick
- Course and prognosis of basaloid squamous cell carcinoma of the head and neck: A case-control study of 62 patients 244
E. Soriano, C. Faure, S. Lantuejoul, E. Reyt, M. Bolla, E. Brambilla and C.A. Righini
- Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer 251
R. Sharma, J. Hook, M. Kumar and H. Gabra

Paediatric Oncology

- Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood 257
A. Borgmann, C. Zinn, R. Hartmann, R. Herold, P. Kaatsch, G. Escherich, A. Möricke, G. Henze and A. von Stackelberg, for the ALL-REZ BFM Study Group

Epidemiology and Cancer Prevention

- Travel times to health care and survival from cancers in Northern England 269
A.P. Jones, R. Haynes, V. Sauerzapf, S.M. Crawford, H. Zhao and D. Forman
- Case-control study on childhood cancer in the vicinity of nuclear power plants in Germany 1980–2003 275
C. Spix, S. Schmiedel, P. Kaatsch, R. Schulze-Rath and M. Blettner
- Incidence of primary liver cancer in Italy between 1988 and 2002: An age-period-cohort analysis 285
L. Dal Maso, M. Lise, P. Zamboni, E. Crocetti, D. Serraino, F. Ricceri, M. Vercelli, V. De Lisi, G. Tagliabue, M. Federico, F. Falcini, T. Cassetti, A. Donato, M. Fusco, M. Budroni, S. Ferretti, R. Tumino, S. Piffer, F. Bellù, L. Mangone, A. Giacomini, S. Vitarelli and S. Franceschi

Metabolic syndrome and cancer risk A. Russo, M. Autelitano and L. Bisanti	293
Experimental Oncology	
Expression profiles in malignant fibrous histiocytomas: Clues for differentiating 'spindle cell' and 'pleomorphic' subtypes M. Scapolan, T. Perin, B. Wassermann, V. Canzonieri, A. Colombatti, F. Italia and P. Spessotto	298
Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity S.M. Guichard, J.S. Macpherson, I. Mayer, E. Reid, M. Muir, M. Dodds, S. Alexander and D.I. Jodrell	310
Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis R. Visone, R. Iuliano, D. Palmieri, I.N. Server, G. Chiappetta, I. De Martino, M. Fedele, S. Costinean, T.M. Oberyshyn, D.F. Kusewitt, C.M. Croce and A. Fusco	318
Erratum	
Erratum to 'When should I start using a new biomarker: Focus on Expression arrays' [EJC Supplement, 5 (2007) 97-104] C. Desmedt and C. Sotiriou	326
Calendar of Forthcoming Meetings	I
NUMBER 3	
News	329
Short Communication	
Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart F. de Nigris, M. Rienzo, C. Schiano, C. Fiorito, A. Casamassimi and C. Napoli	334
Current Perspective	
Current perspectives of epothilones in breast cancer F. Cardoso, E. de Azambuja and L. Dal Lago	341
Reviews	
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients C.C. Zielinski, A. Awada, D.A. Cameron, T. Cufer, M. Martin and M. Aapro	353
Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop P.L. Zinzani, F. d'Amore, E. Bombardieri, C. Brammer, J.G. Codina, T. Illidge, W. Jurczak, W. Linkesch, F. Morschhauser, E. Vandenberghe and A. Van Hoof	366
Lifestyle habits as a contributor to anti-cancer treatment failure F.A. de Jong, A. Sparreboom, J. Verweij and R.H.J. Mathijssen	374
Clinical Oncology	
Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy Y. Okaji, N.H. Tsuno, M. Tanaka, S. Yoneyama, M. Matsushashi, J. Kitayama, S. Saito, Y. Nagura, T. Tsuchiya, J. Yamada, J. Tanaka, N. Yoshikawa, T. Nishikawa, Y. Shuno, T. Todo, N. Saito, K. Takahashi and H. Nagawa	383
Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer O.E. Young, L. Renshaw, E.J. Macaskill, S. White, D. Faratian, J.St.J. Thomas and J.M. Dixon	391

Combination of O ⁶ -methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy T.E. Nakajima, Y. Yamada, T. Shimoda, J. Matsubara, K. Kato, T. Hamaguchi, Y. Shimada, Y. Okayama, T. Oka and K. Shirao	400
Accessibility to targeted oncology drugs in Slovenia and selected European countries M. Kos, M. Obradovic and A. Mrhar	408
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study C. Twelves, J.M. Trigo, R. Jones, F. De Rosa, A. Rakhit, S. Fettner, T. Wright and J. Baselga	419
Paediatric Oncology	
Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic disease C. Bergeron, P. Thiesse, A. Rey, D. Orbach, P. Boutard, C. Thomas, C. Schmitt, M.J. Scopinaro, F. Bernard, M. Stevens and O. Oberlin	427
Epidemiology and Cancer Prevention	
Incidence and time trends of soft tissue sarcomas in German children 1985–2004 – A report from the population-based German Childhood Cancer Registry T. Weihkopf, M. Blettner, T. Dantonello, I. Jung, T. Klingebiel, E. Koscielniak, M. Lückel, C. Spix and P. Kaatsch	432
A Greenwood formula for standard error of the age-standardised relative survival ratio A. Pokhrel, T. Dyba and T. Hakulinen	441
Do cancer predictions work? T. Dyba and T. Hakulinen	448
Educational inequalities in cancer mortality differ greatly between countries around the Baltic Sea N.P.M. Ezendam, I. Stirbu, M. Leinsalu, O. Lundberg, R. Kalediene, B. Wojtyniak, P. Martikainen, J. Mackenbach and A. Kunst	454
A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma C.C. Abnet, N.D. Freedman, A.R. Hollenbeck, J.F. Fraumeni Jr., M. Leitzmann and A. Schatzkin	465
Experimental Oncology	
Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays A. Carlsson, C. Wingren, J. Ingvarsson, P. Ellmark, B. Baldertorp, M. Fernö, H. Olsson and C.A.K. Borrebaeck	472
Calendar of Forthcoming Meetings	I
NUMBER 4	
News	481
Editorial Comment	
QTc prolongation and/or oncology drug development: Who's in danger? M. de Jonge and J. Verweij	486
Current Perspective	
Vulnerable and frail elderly: An approach to the management of the main tumour types S. Monfardini, C. Gridelli, L.M. Pasetto, P. Soubeyran, J.-P. Droz and U. Basso	488
Reviews	
Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development G. Curigliano, G. Spitaleri, H.J. Fingert, F. de Braud, C. Sessa, E. Loh, C. Cipolla, T. De Pas, A. Goldhirsch and R. Shah	494

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials S. Patel and J.R. Zalcberg	501
Lack of association between diagnostic and therapeutic delay and stage of colorectal cancer M. Ramos, M. Esteva, E. Cabeza, J. Llobera and A. Ruiz	510
The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up A.-M. Bouvier, M. Latournerie, V. Jooste, C. Lepage, V. Cottet and J. Faivre	522
Clinical Oncology	
Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402) M. Doffoël, F. Bonnetain, O. Bouché, D. Vetter, A. Abergel, S. Fratté, J.D. Grangé, N. Stremsdoerfer, A. Blanchi, J.P. Bronowicki, F.X. Caroli-Bosc, X. Causse, F. Masskouri, P. Rougier and L. Bedenne, for the Fédération Francophone de Cancérologie Digestive	528
Breast screening with ultrasound in women with mammography-negative dense breasts: Evidence on incremental cancer detection and false positives, and associated cost V. Corsetti, N. Houssami, A. Ferrari, M. Ghirardi, S. Bellarosa, O. Angelini, C. Bani, P. Sardo, G. Remida, E. Galligioni and S. Ciatto	539
Paediatric Oncology	
Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience M. De Ioris, L. Brugieres, A. Zimmermann, J. Keeling, P. Brock, R. Maibach, J. Pritchard, L. Shafford, J. Zsiros, P. Czaudzerna and G. Perilongo	545
Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age J. de Kraker, K.A. Hoefnagel, A.C. Verschuur, B. van Eck, H.M. van Santen and H.N. Caron	551
Epidemiology and Cancer Prevention	
Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland A. Bardin, S. Vaccarella, G.M. Clifford, J. Lissowska, M. Rekosz, P. Bobkiewicz, J. Kupryjańczyk, R. Krynicki, J. Jonska-Gmyrek, A. Danska-Bidzinska, P.J.F. Snijders, C.J.L.M. Meijer, W. Zatonski and S. Franceschi	557
Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3 L. Kotaniemi-Talonen, A. Anttila, N. Malila, J. Tarkkanen, P. Laurila, M. Hakama and P. Nieminen	565
Socioeconomic disparities in psychosocial wellbeing in cancer patients A.E. Simon and J. Wardle	572
Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States M. Sant, C. Allemani, R. De Angelis, A. Carbone, S. de Sanjosé, A.M. Gianni, P. Giraldo, F. Marchesi, R. Marcos-Gragera, C. Martos-Jiménez, M. Maynadié, M. Raphael and F. Berrino, EURO CARE-3 Working Group	579
Surveillance of Barrett's oesophagus: Is it worthwhile? M. Somerville, R. Garside, M. Pitt and K. Stein	588
Experimental Oncology	
Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis T. Sera, Y. Hiasa, T. Mashiba, Y. Tokumoto, M. Hirooka, I. Konishi, B. Matsuura, K. Michitaka, K. Udaka and M. Onji	600
Role of homologous recombination in trabectedin-induced DNA damage M. Tavecchio, M. Simone, E. Erba, I. Chiolo, G. Liberi, M. Foiani, M. D'Incalci and G. Damia	609
Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma M. Junking, C. Wongkham, B. Sripa, K. Sawanyawisuth, N. Araki and S. Wongkham	619

Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours J. Nowak, M. Mosor, I. Ziółkowska, M. Wierzbička, M. Pernak-Schwarz, M. Przyborska, K. Rożnowski, A. Pławski, R. Słomski and D. Januszkiewicz	627
Calendar of Forthcoming Meetings	I
NUMBER 5	
News	631
Editorial Comment	
PAH, genetic susceptibility and breast cancer risk: An update from the Long Island Breast Cancer Study Project M.D. Gammon and R.M. Santella	636
Reviews	
Molecular cancer therapy: Can our expectation be MET? C. Migliore and S. Giordano	641
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer C. Jackson and D. Cunningham	652
Role of FDG PET in the management of childhood lymphomas – case proven or is the jury still out? A. Shankar, F. Fiumara and R. Pinkerton	663
Clinical Oncology	
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies S. Faivre, C. Delbaldo, V. Boige, P. Pautier, J.-C. Soria, F. Namouni, R. Peck, M. Cohen and E. Raymond	674
Implementation of sentinel node biopsy in breast cancer patients in the Netherlands V.K.Y. Ho, M. van der Heiden-van der Loo, E.J.Th. Rutgers, P.J. van Diest, M.G.G. Hobbelen, V.C.G. Tjan-Heijnen, M.J.M. Dirx, A.M.J. Reedijk, J.A.A.M. van Dijk, L.V. van de Poll-Franse, M. Schaapveld and P.H.M. Peeters	683
High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-D-glucose uptake X.C. Nguyen, Y. So, J.-H. Chung, W.W. Lee, S.Y. Park and S.E. Kim	692
Paediatric Oncology	
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy K.-L. Schaefer, M. Eisenacher, Y. Braun, K. Brachwitz, D.H. Wai, U. Dirksen, C. Lanvers-Kaminsky, H. Juergens, D. Herrero, S. Stegmaier, E. Koscielniak, A. Eggert, M. Nathrath, G. Gosheger, D.T. Schneider, C. Bury, R. Diallo-Danebrock, L. Ottaviano, H.E. Gabbert and C. Poremba	699
Epidemiology and Cancer Prevention	
Xeroderma pigmentosum complementation group C genotypes/diploypes play no independent or interaction role with polycyclic aromatic hydrocarbons-DNA adducts for breast cancer risk J. Shen, M.D. Gammon, M.B. Terry, S.L. Teitelbaum, S.M. Eng, A.I. Neugut and R.M. Santella	710
Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine N. Zar, H. Garmo, L. Holmberg and P. Hellman	718

International variation in <i>Helicobacter pylori</i> infection and rates of oesophageal cancer G. Robins, J.E. Crabtree, A. Bailey and D. Forman, on behalf of the EUROGAST Study Group	726
Predictors for the symptomatic prostate cancer patient's delays in seeking care L. Sunny, T. Hopfgarten, J. Adolfsson and G. Steineck	733
Experimental Oncology	
Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of Annexin A1 A. Petrella, C.W. D'Acunto, M. Rodriguez, M. Festa, A. Tosco, I. Bruno, S. Terracciano, M. Taddei, L.G. Paloma and L. Parente	740
Cellular response to oxidative stress and ascorbic acid in melanoma cells overexpressing γ -glutamyltransferase C. Giommarelli, A. Corti, R. Supino, E. Favini, A. Paolicchi, A. Pompella and F. Zunino	750
MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients B.H. Phang, Y.C. Linn, H. Li and K. Sabapathy	760
Calendar of Forthcoming Meetings	I
NUMBER 6	
News	767
Position Paper	
Managing cancer in the EU: The Organisation of European Cancer Institutes (OECI) U. Ringborg, M. Pierotti, G. Storme, T. Tursz and A European Economic Interest Grouping	772
Short Communication	
CDH1 gene polymorphisms, smoking, <i>Helicobacter pylori</i> infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) M. Jenab, J.D. McKay, P. Ferrari, C. Biessy, S. Laing, G.M. Capella Munar, N. Sala, S. Peña, J.B.A. Crusius, K. Overvad, M.K. Jensen, A. Olsen, A. Tjonneland, F. Clavel-Chapelon, M.-C. Boutron-Ruault, R. Kaaks, J. Linseisen, H. Boeing, M.M. Bergmann, A. Trichopoulou, C. Georgila, T. Psaltopoulou, A. Mattiello, P. Vineis, V. Pala, D. Palli, R. Tumino, M.E. Numans, P.H.M. Peeters, H.B. Bueno-de-Mesquita, E. Lund, E. Ardanaz, M.-J. Sánchez, M. Dorronsoro, C. Navarro Sanchez, J.R. Quirós, G. Hallmans, R. Stenling, J. Manjer, S. Régnier, T. Key, S. Bingham, K.-t. Khaw, N. Slimani, S. Rinaldi, P. Boffetta, F. Carneiro, E. Riboli and C. Gonzalez	774
Reviews	
Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts R. von Moos, B.J.K. Thuerlimann, M. Aapro, D. Rayson, K. Harrold, J. Sehouli, F. Scotte, D. Lorusso, R. Dummer, M.E. Lacouture, J. Lademann and A. Hauschild	781
Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: Prognostic value and effects of preoperative radio (chemo) therapy A. Debucquoy, L. Libbrecht, V. Roobrouck, L. Goethals, W. McBride and K. Haustermans	791
Computer aids and human second reading as interventions in screening mammography: Two systematic reviews to compare effects on cancer detection and recall rate P. Taylor and H.W.W. Potts	798
Clinical Oncology	
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) N.S. Reed, C. Mangioni, H. Malmström, G. Scarfone, A. Poveda, S. Pecorelli, S. Tateo, M. Franchi, J.J. Jobsen, C. Coens, I. Teodorovic, I. Vergote and J.B. Vermorken	808

Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy J.H. Schouwink, H. Codrington, H.P. Sleeboom, L.G.M. Kerkhofs and L.W. Wormhoudt	819
---	-----

Paediatric Oncology

Risk of second malignant neoplasms after childhood central nervous system malignant tumours: An international study M. Maule, G. Scélo, G. Pastore, P. Brennan, K. Hemminki, E. Pukkala, E. Weiderpass, J.H. Olsen, E. Tracey, M.L. McBride, D.H. Brewster, V. Pompe-Kirn, J.M. Tonita, E.V. Kliever, K.S. Chia, J.G. Jonasson, C. Martos, C. Magnani and P. Boffetta	830
Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: Long term results of the EORTC CLG 58881 trial A. Uyttebroeck, S. Suciu, G. Laureys, A. Robert, H. Pacquement, A. Ferster, G. Marguerite, F. Mazingue, M. Renard, P. Lutz, X. Rialland, F. Mechinaud, H. Cavé, L. Baila, Y. Bertrand, on behalf of the Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC)	840

Epidemiology and Cancer Prevention

Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer M. Fusco, E. Girardi, P. Piselli, R. Palombino, J. Polesel, C. Maione, P. Scognamiglio, F.A. Pisanti, M. Solmone, P.D. Cicco, G. Ippolito, S. Franceschi, D. Serraino, for the Collaborating Study Group	847
Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk? D. Campa, P. Vodicka, B. Pardini, J. Novotny, A. Försti, K. Hemminki, R. Barale and F. Canzian	854
Evaluation of service mammography screening impact in Italy: The contribution of hazard analysis E. Paci, E. Coviello, G. Miccinesi, D. Puliti, L. Cortesi, V.D. Lisi, S. Ferretti, L. Mangone, V. Perlangeli, A. Ponti, A. Ravaoli, P.S. de' Bianchi, N. Segnan, F. Stracci, R. Tumino, M. Zarcone, M. Zorzi, M. Zappa and IMPACT Working Group	858

Experimental Oncology

Low telomerase activity: Possible role in the progression of human medullary thyroid carcinoma G. Stadler, M. Wieser, B. Streubel, A. Stift, J. Friedl, M. Gnant, B. Niederle, A. Beham, H. Katinger, R. Pfragner, J. Grillari and R. Voglauer	866
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma F. Bersani, R. Taulli, P. Accornero, A. Morotti, S. Miretti, T. Crepaldi and C. Ponzetto	876
Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data N. Kittaka, I. Takemasa, Y. Takeda, S. Marubashi, H. Nagano, K. Umeshita, K. Dono, K. Matsubara, N. Matsuura and M. Monden	885
Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels R.D. Verschoyle, P. Greaves, K. Patel, D.A. Marsden, K. Brown, W.P. Steward and A.J. Gescher	898

Calendar of Forthcoming Meetings	I
----------------------------------	---

NUMBER 7

News	907
Reviews	
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab M. Marty and X. Pivot	912
Amplifying tumour-specific replication lesions by DNA repair inhibitors – A new era in targeted cancer therapy T. Helleday	921

A potential paradox in prostate adenocarcinoma progression: Oestrogen as the initiating driver P.B. Singh, S.S. Matanhelia and F.L. Martin	928
Systematic review of the association between circulating interleukin-6 (IL-6) and cancer K. Heikkilä, S. Ebrahim and D.A. Lawlor	937
Prognostic versus predictive value of biomarkers in oncology C.N.A.M. Oldenhuis, S.F. Oosting, J.A. Gietema and E.G.E. de Vries	946
Clinical Oncology	
Subanaesthetic ketamine spares postoperative morphine and controls pain better than standard morphine does alone in orthopaedic-oncological patients Y. Kollender, J. Bickels, D. Stocki, N. Maruoani, S. Chazan, A. Nirkin, I. Meller and A.A. Weinbroum	954
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: A cost-effectiveness analysis J. Norum, A.I. Hagen, L. Mæhle, J. Apold, J. Burn and P. Møller	963
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour I. Chabot, J. LeLorier and M.E. Blackstein	972
Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital V. Karavasilis, L. Digue, T. Arkenau, D. Eaton, S. Stapleton, J. de Bono, I. Judson and S. Kaye	978
Paediatric Oncology	
Second cancers in patients with the Ewing sarcoma family of tumours F. Navid, C. Billups, T. Liu, M.J. Krasin and C. Rodriguez-Galindo	983
Epidemiology and Cancer Prevention	
Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer A.P. Jones, R. Haynes, V. Sauerzapf, S.M. Crawford, H. Zhao and D. Forman	992
The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival analysis of 3892 patients J.-H. Wang, C.-S. Changchien, T.-H. Hu, C.-M. Lee, K.-M. Kee, C.-Y. Lin, C.-L. Chen, T.-Y. Chen, Y.-J. Huang and S.-N. Lu	1000
Tamoxifen exposure in relation to gastric adenocarcinoma development E. Chandanos, M. Lindblad, C.A. Rubio, C. Jia, M. Warner, J.-Å. Gustafsson and J. Lagergren	1007
Experimental Oncology	
HMG2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias G. Chiappetta, A. Ferraro, E. Vuttariello, M. Monaco, F. Galdiero, V. De Simone, D. Califano, P. Pallante, G. Botti, L. Pezzullo, G.M. Pierantoni, M. Santoro and A. Fusco	1015
Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells I. Hashimoto, K. Koizumi, M. Tatamatsu, T. Minami, S. Cho, N. Takeno, A. Nakashima, H. Sakurai, S. Saito, K. Tsukada and I. Saiki	1022
Lineage-specific silencing of human IL-10 gene expression by promoter methylation in cervical cancer cells A. Szalmás, F. Bánáti, A. Koroknai, B. László, E. Fehér, D. Salamon, L. Gergely, J. Minárovits and J. Kónya	1030
Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma R.A. Perego, M. Corizzato, P. Brambilla, S. Ferrero, C. Bianchi, E. Fasoli, S. Signorini, B. Torsello, L. Invernizzi, S. Bombelli, V. Angeloni, M. Pitto, C. Battaglia, V. Proserpio, F. Magni, G. Galasso and P. Mocarelli	1039

MUC4 interacts with ErbB2 in human gallbladder carcinoma: Potential pathobiological implications N. Miyahara, J. Shoda, K. Ishige, T. Kawamoto, T. Ueda, R. Taki, N. Ohkohchi, I. Hyodo, M.B. Thomas, S. Krishnamurthy, K.L. Carraway and T. Irimura	1048
The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients K. Kadota, C.-I. Huang, D. Liu, M. Ueno, Y. Kushida, R. Haba and H. Yokomise	1057
<i>Calendar of Forthcoming Meetings</i>	I

NUMBER 8

Palliative Medicine – the Art and the Science

Guest Editor: M. Fallon

Terminology: the historical perspective, evolution and current usage – room for confusion? M. Fallon and J. Smyth	1069
Cancer pain assessment – Can we predict the need for specialist input? R.L. Fainsinger and C.L. Nekolaichuk	1072
Management of Cancer Pain: Basic Principles and Neuropathic Cancer Pain B. Laird, L. Colvin and M. Fallon	1078
Challenges in cancer pain management–bone pain L. Colvin and M. Fallon	1083
Neuropathic pain in cancer C.E. Urch and A.H. Dickenson	1091
Cancer-related fatigue P.C. Stone and O. Minton	1097
Management of malignant bowel obstruction C.I. Ripamonti, A.M. Easson and H. Gerdes	1105
Breathlessness in cancer patients E. Cachia and S.H. Ahmedzai	1116
Cancer cachexia: Developing multimodal therapy for a multidimensional problem K.C.H. Fearon	1124
Distress in palliative care patients: Developing patient-centred approaches to clinical management M. Lloyd-Williams, J. Reeve and D. Kissane	1133
Paediatric palliative care: Coming of age in oncology? R. McCulloch, M. Comac and F. Craig	1139
Predicting survival in patients with advanced disease P. Glare, C. Sinclair, M. Downing, P. Stone, M. Maltoni and A. Viganò	1146
End of life issues N. Sykes	1157
Communication: Common challenging scenarios in cancer care R. Owen and D. Jeffrey	1163
Hope in advanced cancer patients S.E. McClement and H.M. Chochinov	1169

Palliative care research – priorities and the way forward S. Kaasa and L. Radbruch	1175
---	------

NUMBER 9

News	1181
-------------	------

Short Communication

Women show mixed intentions regarding the uptake of HPV vaccinations in pre-adolescents: A questionnaire study I.J. Korfage, M.-L. Essink-Bot, R. Daamen, F. Mols and M. van Ballegooijen	1186
--	------

Current Perspective

When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? P. Hamberg, P.C.M.S. Verhagen and R. de Wit	1193
--	------

Adjuvant chemotherapy after resection of liver metastases from colorectal cancer I. Taylor	1198
---	------

Review

Synovial sarcoma of children and adolescents: The prognostic role of axial sites A. Ferrari, G. Bisogno, R. Alaggio, G. Cecchetto, P. Collini, A. Rosolen, C. Meazza, P. Indolfi, A. Garaventa, L. De Sio, P. D'Angelo, P. Tamaro, M. Casanova and M. Carli	1202
--	------

Clinical Oncology

Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882) J. Hildebrand, T. Gorlia, J.M. Kros, D. Afra, M. Frenay, A. Omuro, R. Stupp, D. Lacombe, A. Allgeier and M.J. van den Bent, on behalf of the EORTC Brain Tumour Group investigators	1210
---	------

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance A. Torsello, C. Garufi, M. Cosimelli, M.G. Diodoro, M. Zeuli, B. Vanni, C. Campanella, C. D'Angelo, I. Sperduti, R.P. Donnorso, F. Cognetti, E. Terzoli and M. Mottolese, on behalf of the Colorectal Disease Management Team, Regina Elena Cancer Institute, Rome, Italy	1217
--	------

Introduction of additional double reading of mammograms by radiographers: Effects on a biennial screening programme outcome L.E.M. Duijm, J.H. Groenewoud, J. Fracheboud, B.M. van Ineveld, R.M.H. Roumen and H.J. de Koning	1223
---	------

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer E. Martinez-Balibrea, A. Abad, E. Aranda, J. Sastre, J.L. Manzano, E. Díaz-Rubio, A. Gómez-España, J. Aparicio, T. García, I. Maestu, A. Martínez-Cardús, A. Ginés and E. Guino, on behalf of the Spanish Group for the Treatment of Digestive Tumours (TTD group)	1229
--	------

Relationship between nutritional status and quality of life in patients with cancer A. Nourissat, M.P. Vasson, Y. Merrouche, C. Bouteloup, M. Goutte, D. Mille, J.P. Jacquin, O. Collard, P. Michaud and F. Chauvin	1238
--	------

Paediatric Oncology

Health related quality of life in the first year after diagnosis in children with brain tumours compared with matched healthy controls; a prospective longitudinal study A. Penn, S.P. Lewis, L.P. Hunt, R.I. Shortman, M.C.G. Stevens, R.L. McCarter, A.L. Curran and P.M. Sharples	1243
---	------

Epidemiology and Cancer Prevention

Association of endothelin-converting enzyme-1b C-338A polymorphism with gastric cancer risk: A case-control study H. Gu, L. Yang, N. Tang, B. Zhou, H. Zhu, Q. Sun, R. Cong and B. Wang	1253
--	------

Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study N. Becker, D. Liebermann, H. Wesch and G. Van Kaick	1259
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL) M. Harland, A.M. Goldstein, K. Kukalizch, C. Taylor, D. Hogg, S. Puig, C. Badenas, N. Gruis, J. ter Huurne, W. Bergman, N.K. Hayward, M. Stark, H. Tsao, M.A. Tucker, M.T. Landi, G.B. Scarra, P. Ghiorzo, P.A. Kanetsky, D. Elder, G.J. Mann, E.A. Holland, D.T. Bishop and J.N. Bishop, members of GenoMEL, the Melanoma Genetics Consortium	1269
Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: Results from a long-term follow-up study of Italian patients S. Rosso, F. Sera, N. Segnan and R. Zanetti	1275
Survival of children with cancer in Italy, 1989–98. A report from the hospital based registry of the Italian Association of Paediatric Haematology and Oncology (AIEOP) A. Pession, E. Dama, R. Rondelli, C. Magnani, M. De Rosa, F. Locatelli, F. Fagioli, R. Haupt, M. Jankovic, B. Terracini, F. Merletti and G. Pastore, on behalf of the Italian Association of Paediatric Haematology and Oncology	1282
Experimental Oncology	
Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics G. Deng, S. Kakar, H. Tanaka, K. Matsuzaki, S. Miura, M.H. Sleisenger and Y.S. Kim	1290
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity L. Tentori, A. Muzi, A.S. Dorio, S. Bultrini, E. Mazzon, P.M. Lacal, G.M. Shah, J. Zhang, P. Navarra, G. Nocentini, S. Cuzzocrea and G. Graziani	1302
Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C P. Jasinski, K. Terai, P. Zwolak and A.Z. Dudek	1315
LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer J.B. Weise, P. Rudolph, A. Heiser, M.-L. Kruse, J. Hedderich, C. Cordes, M. Hoffmann, O. Brant, P. Ambrosch, K. Csiszar and T. Görögh	1323
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968 C. Pisano, V. Zuco, M. De Cesare, V. Benedetti, L. Vesci, R. Foderà, F. Bucci, C. Aulicino, S. Penco, P. Carminati and F. Zunino	1332
Calendar of Forthcoming Meetings	I

NUMBER 10

Cancer Control in Europe: State of the Art in 2008

Guest Editors: J.W. Coebergh and T. Albreht

Editorial Comment

Should the EU also wage war against cancer? And if so, how? Foreword and afterthoughts to this special issue on cancer control at the European level J.W. Coebergh and T. Albreht	1341
Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s H.E. Karim-Kos, E. de Vries, I. Soerjomataram, V. Lemmens, S. Siesling and J.W.W. Coebergh	1345
Cancer causes and prevention: A condensed appraisal in Europe in 2008 J.M. Martin-Moreno, I. Soerjomataram and G. Magnusson	1390

Cancer screening: Evidence and practice in Europe 2008 M. Hakama, M.P. Coleman, D.-M. Alexe and A. Auvinen	1404
Dying with cancer, living well with advanced cancer I.J. Higginson and M. Costantini	1414
Closing the gap: Cancer in Central and Eastern Europe (CEE) W. Zatoński and J. Didkowska	1425
Obstacles to European research projects with data and tissue: Solutions and further challenges E.-B. van Veen	1438
Making progress against cancer in Europe in 2008 T. Albrecht, M. McKee, D.-M. Alexe, M.P. Coleman and J.M. Martin-Moreno	1451
Improving cancer control in the European Union: Conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007 J. Gouveia, M.P. Coleman, R. Haward, R. Zanetti, M. Hakama, J.M. Borras, M. Primic-Žakelj, H.J. de Koning and L. Travado	1457
Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries A. Gondos, F. Bray, D.H. Brewster, J.W.W. Coebergh, T. Hakulinen, M.L.G. Janssen-Heijnen, J. Kurtinaitis and H. Brenner, The EUNICE Survival Working Group	1463

NUMBER 11

News	1477
Editorials	
An invitation to correspond with us! J.F. Smyth	1482
What colour is my cancer? Engaging teenage and young adult patients with their disease S. Morgan, P. Roberts and J. Stahlschmidt	1483
Short Communication	
Large increase in a Dutch woman's lifetime risk of developing breast cancer E. Paap, M.J.M. Broeders, G. van Schoor, J.D.M. Otten and A.L.M. Verbeek	1485
Current Perspective	
Loading doses for costly cancer biologicals: Sound pharmacology or unnecessary extravagance? R.J. Epstein and B.M.Y. Cheung	1488
Position Paper	
Loading doses for costly cancer biologicals: A cause for concern or tilting at windmills? I.M. Hennig and C. Twelves	1493
Reviews	
Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – A systematic review to evaluate the added value in supporting clinical decision making F. Efficace, G. Kemmler, M. Vignetti, F. Mandelli, S. Molica and B. Holzner	1497
Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies S. Wolf, D. Barton, L. Kottschade, A. Grothey and C. Loprinzi	1507
Multiple ways of C/EBP α inhibition in myeloid leukaemia A.K. Trivedi, P. Pal, G. Behre and S.M. Singh	1516

Clinical Oncology

- The validity of tumour diameter assessed by magnetic resonance imaging and gross specimen with regard to tumour volume in cervical cancer patients 1524
D.C. Jung, W. Ju, H.J. Choi, S. Kang, S. Park, C.W. Yoo and S.-Y. Park

- Measurement and interpretation of social distress using the social difficulties inventory (SDI) 1529
P. Wright, L. Marshall, A.B. Smith, G. Velikova and P. Selby

- 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? 1536
H.-T. Arkenau, D. Olmos, J.E. Ang, J. Barriuso, V. Karavasilis, S. Ashley, J. de Bono, I. Judson and S. Kaye

- Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance 1541
H.O. Habashy, D.G. Powe, E.A. Rakha, G. Ball, C. Paish, J. Gee, R.I. Nicholson and I.O. Ellis

Paediatric Oncology

- The prognostic impact of functional imaging with ^{123}I -mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97 1552
M. Schmidt, T. Simon, B. Hero, H. Schicha and F. Berthold

Epidemiology and Cancer Prevention

- Hospital differences in patient satisfaction with care for breast, colorectal, lung and prostate cancers 1559
C. Sherlaw-Johnson, P. Datta and M. McCarthy

- Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden 1566
M. Sundelöf, J. Lagergren and W. Ye

- Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer 1572
T. Langsenlehner, U. Langsenlehner, W. Renner, P. Krippel, R. Mayer, T.C. Wascher and K.S. Kapp

Experimental Oncology

- Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis 1577
C. Moser, P. Schachtschneider, S.A. Lang, A. Gaumann, A. Mori, J. Zimmermann, H.J. Schlitt, E.K. Geissler and O. Stoeltzing

- Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation 1587
P. Dua and R.P. Gude

- Hepatitis B virus X protein disrupts DNA interstrand crosslinking agent mitomycin C induced ATR dependent intra-S-phase checkpoint 1596
X.-Y. Wu, J.-J. Qian, Y. Lin and M.-H. Zheng

- Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions 1603
H. Yang, S.M. Lippman, M. Huang, J. Jack Lee, W. Wang, M.R. Spitz and X. Wu

Corrigendum

- Corrigendum to "Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)" [European Journal of Cancer, 44 (2008) 808–818] 1612
N.S. Reed, C. Mangioni, H. Malmström, G. Scarfone, A. Poveda, S. Pecorelli, S. Tateo, M. Franchi, J.J. Jobsen, C. Coens, I. Teodorovic, I. Vergote and J.B. Vermorken

Calendar of Forthcoming Meetings

I

NUMBER 12

News	1613
Editorial Comments	
Enhancing patient care by the professional development of clinical staff: A self-directed educational manual for staff working with parents with advanced cancer F. Cathcart	1618
Radio-chemotherapy in rectal cancer J. Cassidy	1620
The management of cerebral metastasis from germ cell cancer; walking the tightrope R. de Wit, M. van den Bent and W. Kirkels	1622
Reviews	
Enhancing the supportive care of parents with advanced cancer: Development of a self-directed educational manual J. Turner, A. Clavarino, P. Yates, M. Hargraves, V. Connors and S. Hausmann	1625
Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk factors F. Linkov, R. Edwards, J. Balk, Z. Yurkovetsky, B. Stadterman, A. Lokshin and E. Taioli	1632
Angiogenesis as a target in neuroblastoma J. Rössler, M. Taylor, B. Geoerger, F. Farace, J. Lagodny, R. Peschka-Süss, C.M. Niemeyer and G. Vassal	1645
Clinical Oncology	
Phase I trial of r viscumine (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001) L. Bergmann, S. Aamdal, S. Marreaud, D. Lacombe, M. Herold, T. Yamaguchi, K. Wilhelm-Ogunbiyi, H. Lentzen and H. Zwierzina	1657
Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy K. Oechsle, C. Kollmannsberger, F. Honecker, I. Boehlke and C. Bokemeyer	1663
The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer P.T. Truong, V. Vinh-Hung, G. Cserni, W.A. Woodward, P. Tai and G. Vlastos, the authors are members of the International Nodal Ratio Working Group	1670
Impact of whole-body ¹⁸ F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients M. Zafra, F. Ayala, E. Gonzalez-Billalabeitia, E. Vicente, P. Gonzalez-Cabezas, T. García, J.A. Macías and V. Vicente	1678
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)-XK469 in patients with advanced solid tumours S.D. Undevia, F. Innocenti, J. Ramirez, L. House, A.A. Desai, L.A. Skoog, D.A. Singh, T. Karrison, H.L. Kindler and M.J. Ratain	1684
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study H.P. Kalofonos, A. Bamias, A. Koutras, P. Papakostas, G. Basdanis, E. Samantas, M. Karina, D. Misailidou, N. Pisanidis, G. Pentheroudakis, T. Economopoulos, C. Papadimitriou, D.V. Skarlos, D. Pectasides, M. Stavropoulos, D. Bafaloukos, D. Kardamakis, C. Karanikiotis, G. Vourli and G. Fountzilas	1693
Epidemiology and Cancer Prevention	
No improvement in renal cell carcinoma survival: A population-based study in the Netherlands K.K.H. Aben, T.K. Luth, M.L.G. Janssen-Heijnen, P.F. Mulders, L.A. Kiemeny and D.J. van Spronsen	1701

Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radio-therapy M. den Dulk, P. Krijnen, C.A.M. Marijnen, H.J. Rutten, L.V. van de Poll-Franse, H. Putter, E. Meershoek-Klein Kranenbarg, M.L.E.A. Jansen-Landheer, J.-W.W. Coebergh and C.J.H. van de Velde	1710
Environmental risk factors for relapse of melanoma S. Beswick, P. Affleck, F. Elliott, E. Gerry, A. Boon, L. Bale, C. Nolan, J.H. Barrett, C. Bertram, J. Marsden, D.T. Bishop and J.A. Newton-Bishop	1717
In vitro radiosensitisation by trabectedin in human cancer cell lines J. Romero, I. Zapata, S. Córdoba, J.M. Jimeno, J.A. López-Martín, J.C. Tercero, A. De La Torre, J.A. Vargas, R. Molerón and R. Sánchez-Prieto	1726
Anti-tumour activity of GS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model N. Shimazaki, N. Togashi, M. Hanai, T. Isoyama, K. Wada, T. Fujita, K. Fujiwara and S. Kurakata	1734
Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system M. Dalamaga, K. Karmaniolas, A. Nikolaidou, J. Chamberland, A. Hsi, A. Dionyssiou-Asteriou and C.S. Mantzoros	1744
Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation J.T. Auman, R. Church, S.-Y. Lee, M.A. Watson, J.W. Fleshman and H.L. Mcleod	1754
Expression profiling of angiogenic genes for the characterisation of colorectal carcinoma A. Carrer, S. Zacchigna, A. Balani, V. Pistan, A. Adami, F. Porcelli, M. Scaramucci, M. Roseano, A. Turollo, M.C. Prati, M. Dell'Omodarme, N. de Manzini and M. Giacca	1761
Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells J.S. Lewis-Wambi, H.E. Cunliffe, H.R. Kim, A.L. Willis and V.C. Jordan	1770
Calendar of Forthcoming Meetings	I
NUMBER 13	
News	1781
Editorial Comment	
A new anti-cancer drug in the market: Good news for investors or for patients? G. Apolone, G. Tafuri, F. Trotta and S. Garattini	1786
Short Communication	
Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer A. Rody, T. Karn, E. Ruckhaeberle, L. Hanker, R. Gaetje, U. Holtrich and M. Kaufmann	1789
Reviews	
Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials K. Cocks, M.T. King, G. Velikova, P.M. Fayers and J.M. Brown	1793
Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know L.S. Velentzis, J.V. Woodside, M.M. Cantwell, A.J. Leathem and M.R. Keshtgar	1799

European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer F. Lordick, T. Ruers, D.E. Aust, L. Collette, R.J. Downey, M. El Hajjam, P. Flamen, K. Haustermans, D. Ilson, C. Julié, B.J. Krause, H. Newiger, K. Ott, A. Roth, E. Van Cutsem, W.A. Weber and M.P. Lutz	1807
Clinical Oncology	
Randomised controlled trials of palliative care – a survey of the views of advanced cancer patients and their relatives C.D. White, J.R. Hardy, K.S. Gilshenan, M.A. Charles and C.R. Pinkerton	1820
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours S. Cresta, C. Sessa, C.V. Catapano, E. Gallerani, D. Passalacqua, A. Rinaldi, F. Bertoni, L. Viganò, M. Maur, G. Capri, E. Maccioni, D. Tosi and L. Gianni	1829
Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression M.G.W. Scheer, T.H. Stollman, O.C. Boerman, K. Verrijp, F.C.G.J. Sweep, W.P.J. Leenders, T.J.M. Ruers and W.J.G. Oyen	1835
Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas M. Christie-Large, S.L.J. James, L. Tiessen, A.M. Davies and R.J. Grimer	1841
Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands M.P.P. Sukel, L.V. van de Poll-Franse, G.A.P. Nieuwenhuijzen, G. Vreugdenhil, R.M.C. Herings, J.W.W. Coebergh and A.C. Voogd	1846
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate R. Sciot, M. Debiec-Rychter, S. Daugaard, C. Fisher, F. Collin, M. van Glabbeke, J. Verweij, J.-Y. Blay, P.C.W. Hogendoorn, On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Trials Group	1855
Paediatric Oncology	
Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients T. Lehrnbecher, H.-J. Laws, A. Boehm, M. Dworzak, G. Janssen, A. Simon and A.H. Groll	1861
Epidemiology and Cancer Prevention	
Risk for unemployment of cancer survivors: A Danish cohort study K. Carlsen, S.O. Dalton, F. Diderichsen and C. Johansen	1866
Experimental Oncology	
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer G. Perrone, P.A. Ruffini, V. Catalano, C. Spino, D. Santini, P. Muretto, C. Spoto, C. Zingaretti, V. Sisti, P. Alessandroni, P. Giordani, A. Cicetti, S. D'Emidio, S. Morini, A. Ruzzo, M. Magnani, G. Tonini, C. Rabitti and F. Graziano	1875
Recombinant human VEGF _{165b} protein is an effective anti-cancer agent in mice E.S. Rennel, M.A. Hamdollah-Zadeh, E.R. Wheatley, A. Magnussen, Y. Schöler, S.P. Kelly, C. Finucane, D. Ellison, S. Cebe-Suarez, K. Ballmer-Hofer, S. Mather, L. Stewart, D.O. Bates and S.J. Harper	1883
Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer M. Hartel, G. Narla, M.N. Wenthe, N.A. Giese, M.E. Martignoni, J.A. Martignetti, H. Friess and S.L. Friedman	1895
VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis L.J.A.C. Hawinkels, K. Zuidwijk, H.W. Verspaget, E.S.M. de Jonge-Muller, W. van Duijn, V. Ferreira, R.D. Fontijn, G. David, D.W. Hommes, C.B.H.W. Lamers and C.F.M. Sier	1904

Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide P.M. Lacal, V. Morea, F. Ruffini, A. Orecchia, A.S. Dorio, C.M. Failla, S. Soro, L. Tentori, G. Zambruno, G. Graziani, A. Tramontano and S. D'Atri	1914
--	------

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition A. Bozec, F.-X. Gros, F. Penault-Llorca, P. Formento, A. Cayre, C. Dental, M.-C. Etienne-Grimaldi, J.-L. Fischel and G. Milano	1922
--	------

Corrigendum

Corrigendum to "Promises borne out in clinical studies" [EJC Supplements 6 (5) (2008) 15–24] D. Cameron	1931
--	------

Calendar of Forthcoming Meetings	I
---	----------

NUMBER 14

CANULI – Social Inequality in Cancer Incidence and Survival in Denmark

Guest Editors: S. Oksbjerg Dalton, J. Schüz, C. Johansen, S. Krüger Kjær, G. Engholm, H.H. Storm and J.H. Olsen

Editorial Comment

Social inequalities in cancer incidence and cancer survival: Lessons from Danish studies G. Menvielle and A. Kunst	1933
---	------

Social inequality and incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: Background, aims, material and methods S.O. Dalton, M. Steding-Jessen, M. Gislum, K. Frederiksen, G. Engholm and J. Schüz	1938
--	------

Social inequality and incidence of and survival from cancers of the mouth, pharynx and larynx in a population-based study in Denmark, 1994–2003 Z.J. Andersen, C.F. Lassen and I.H. Clemmensen	1950
---	------

Social inequality and incidence of and survival from cancers of the oesophagus, stomach and pancreas in a population-based study in Denmark, 1994–2003 R. Bastrup, M. Sørensen, J. Hansen, R.D. Hansen, H. Würtzen and J.F. Winther	1962
--	------

Social inequality and incidence of and survival from cancers of the colon and rectum in a population-based study in Denmark, 1994–2003 R. Egeberg, J. Halkjær, N. Rottmann, L. Hansen and I. Holten	1978
--	------

Social inequality and incidence of and survival from lung cancer in a population-based study in Denmark, 1994–2003 S.O. Dalton, M. Steding-Jessen, G. Engholm, J. Schüz and J.H. Olsen	1989
---	------

Social inequality and incidence of and survival from breast cancer in a population-based study in Denmark, 1994–2003 K. Carlsen, M.T. Høybye, S.O. Dalton and A. Tjønneland	1996
--	------

Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994–2003 K.E. Jensen, C.G. Hannibal, A. Nielsen, A. Jensen, B. Nøhr, C. Munk and S.K. Kjær	2003
---	------

Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994–2003 K. Marså, N.F. Johnsen, P.E. Bidstrup, C.T. Johannesen-Henry and S. Friis	2018
---	------

Social inequality and incidence of and survival from cancers of the kidney and urinary bladder in a population-based study in Denmark, 1994–2003 K.T. Eriksen, A. Petersen, A.H. Poulsen, I. Deltour and O. Raaschou-Nielsen	2030
---	------

Social inequality and incidence of and survival from malignant melanoma in a population-based study in Denmark, 1994–2003 <i>F. Birch-Johansen, G. Hvilsom, T. Kjær and H. Storm</i>	2043
Social inequality and incidence of and survival from tumours of the central nervous system in a population-based study in Denmark, 1994–2003 <i>L.S. Schmidt, H. Nielsen, S. Schmiedel and C. Johansen</i>	2050
Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994–2003 <i>N. Roswall, A. Olsen, J. Christensen, K. Rugbjerg and L. Møller</i>	2058
Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: Summary of findings <i>S.O. Dalton, J. Schüz, G. Engholm, C. Johansen, S.K. Kjær, M. Steding-Jessen, H.H. Storm and J.H. Olsen</i>	2074

NUMBER 15

News	2087
Editorials	
Progression-free versus overall survival and adequate powering in randomised studies <i>N. Manek, C. Apostolopoulos and J. Stebbing</i>	2092
Patient migration, access to expertise and optimal patterns of care <i>M.C.G. Stevens</i>	2095
Short Communications	
Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas <i>P. Mhawech-Fauceglia, A. Allal, K. Odunsi, C. Andrews, F.R. Herrmann and B. Huard</i>	2097
Patterns of domestic migrations and access to childhood cancer care centres in Italy: A report from the hospital based registry of the Italian Association of Pediatric Hematology and Oncology (AIEOP) <i>E. Dama, R. Rondelli, M. De Rosa, M. Aricò, M. Carli, F.F. Bellani, C. Magnani, F. Merletti, G. Pastore and A. Pession</i>	2101
Current Perspectives	
Clinical trials for children with cancer in Europe – Still a long way from harmonisation: A report from SIOP Europe <i>K. Pritchard-Jones</i>	2106
The First European Conference on Infections in Leukaemia – ECIL1: A current perspective <i>F. Meunier and C. Lukan</i>	2112
Position Paper	
‘Breast awareness’ and ‘breast self-examination’ are not the same. What do these terms mean? Why are they confused? What can we do? <i>H. Thornton and R.R. Pillarisetti</i>	2118
Reviews	
Statins and cancer: A systematic review and meta-analysis <i>J. Kuoppala, A. Lamminpää and E. Pukkala</i>	2122
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials <i>N. Magné, C. Chargari, P. Castadot, M. Ghalibafian, J.-C. Soria, C. Haie-Meder, J. Bourhis and E. Deutsch</i>	2133

Potential roles for the PIM1 kinase in human cancer – A molecular and therapeutic appraisal N. Shah, B. Pang, K.-G. Yeoh, S. Thorn, C.S. Chen, M.B. Lilly and M. Salto-Tellez	2144
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies S. Chowdhury, J.M.G. Larkin and M.E. Gore	2152
Clinical Oncology	
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery) J.S. Graham, R. Plummer, C. McCoy, K. Kowal, H. Wiesinger, K. Detjen, H. Calvert, B. Wiedenmann and J. Cassidy	2162
Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study G. Aravantinos, G. Fountzilas, A. Bamias, I. Grimani, S. Rizos, H.P. Kalofonos, D.V. Skarlos, T. Economopoulos, P.A. Kosmidis, G.P. Stathopoulos, E. Briasoulis, D. Pectasides, E. Samantas, E. Timotheadou, C. Papadimitriou, A. Papanikolaou, A. Onyenadum, P. Papakostas, D. Bafaloukos and M.A. Dimopoulos	2169
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer A. Bottomley, C. Debruyne, E. Felip, M. Millward, L. Thiberville, G. D' Addario, L. Rome, P. Zatloukal, C. Coens and G. Giaccone	2178
Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions G. Cserni, S. Bianchi, V. Vezzosi, P. van Diest, C. van Deurzen, I. Sejbien, P. Regitnig, M. Asslaber, M.P. Foschini, A. Sapino, I. Castellano, G. Callagy, E. Arkoumani, J. Kulka and C.A. Wells	2185
Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis E. Goldberg, A. Gafter-Gvili, E. Robenshtok, L. Leibovici and M. Paul	2192
Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) I. Popov, A. Carrato, A. Sobrero, M. Vincent, D. Kerr, R. Labianca, A.R. Bianco, M. El-Serafi, L. Bedenne, B. Paillet, E. Mini, E. Sanches, J. Welch, L. Collette, M. Praet and J. Wils	2204
Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study L. Wedlake, K. Thomas, C. McGough and H.J.N. Andreyev	2212
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007 N. Wilcken and R. Dear	2218
Paediatric Oncology	
Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia M. Mosor, I. Ziolkowska, D. Januszkiewicz-Lewandowska and J. Nowak	2226
Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany A. Laengler, C. Spix, G. Seifert, S. Gottschling, N. Graf and P. Kaatsch	2233
Epidemiology and Cancer Prevention	
Associations between XPC polymorphisms and risk of cancers: A meta-analysis L. Qiu, Z. Wang, X. Shi and Z. Wang	2241
Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms V. Dancourt, C. Lejeune, C. Lepage, M.C. Gailliard, B. Meny and J. Faivre	2254

Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients A. Mann, E. Hogdall, S.J. Ramus, R.A. DiCioccio, C. Hogdall, L. Quaye, V. McGuire, A.S. Whittemore, M. Shah, D. Greenberg, D.F. Easton, B.A.J. Ponder, S.K. Kjaer, S.A. Gayther, D.J. Thompson, P.D.P. Pharoah and H. Song	2259
---	------

Experimental Oncology

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer C. Feder-Mengus, S. Wyler, T. Hudolin, R. Ruszat, L. Bubendorf, A. Chiarugi, M. Pittelli, W.P. Weber, A. Bachmann, T.C. Gasser, T. Sulser, M. Heberer, G.C. Spagnoli and M. Provenzano	2266
--	------

Manipulation of oxidative stress to induce cell death in Ewing's sarcoma family of tumours T. Magwere, S.S. Myatt and S.A. Burchill	2276
--	------

Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population V. Deschoolmeester, N. Van Damme, M. Baay, K. Claes, E. Van Marck, F.J. Baert, W. Wuyts, M. Cabooter, J. Weyler, P. Vermeulen, F. Lardon, J.B. Vermorken and M. Peeters	2288
--	------

Targeting $\alpha 7$ -nicotinic receptor for the treatment of pleural mesothelioma A. Catassi, L. Paleari, D. Servent, F. Sessa, L. Dominioni, E. Ognio, M. Cilli, P. Vacca, M. Mingari, G. Gaudino, P. Bertino, M. Paolucci, A. Calcaterra, A. Cesario, P. Granone, R. Costa, M. Ciarlo, A. Alama and P. Russo	2296
--	------

Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas V. Granci, F. Bibeau, A. Kramar, F. Boissière-Michot, S. Thézénas, A. Thirion, C. Gongora, P. Martineau, M. Del Rio and M. Ychou	2312
---	------

Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification D.S.A. Nuyten, T. Hastie, J.A. Chi, H.Y. Chang and M.J. van de Vijver	2319
--	------

Corrigenda

Corrigendum to "Management of toxicity in patients receiving therapy with bevacizumab" [EJC Suppl. 6(6) (2008) 29–39] D. Miles	2330
---	------

Corrigendum to "Bevacizumab in the first-line treatment of metastatic breast cancer" [EJC Suppl. 6(6) (2008) 21–28] D. Cameron	2331
---	------

Calendar of Forthcoming Meetings	I
----------------------------------	---

NUMBER 16

News	2333
------	------

Editorial Comment

Enough rehabilitation for our elderly cancer patients? E. Morello, R. Sandri and S. Monfardini	2338
---	------

Short Communication

Treatment of primary rectal squamous cell carcinoma by primary chemoradiotherapy: Should surgery still be considered a standard of care? J. Clark, S. Cleator, R. Goldin, C. Lowdell, A. Darzi and P. Ziprin	2340
---	------

Current Perspectives

Hormone replacement therapy and the risk of breast cancer J. Cuzick	2344
--	------

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit? F. ALM Eskens and S. Sleijfer	2350
---	------

Reviews

- Marine pharmacology in 2005–2006: Antitumour and cytotoxic compounds 2357
A.M.S. Mayer and K.R. Gustafson
- Global child health priorities: What role for paediatric oncologists? 2388
S.J. Kellie and S.C. Howard
- Oestrogen and the enigmatic male predominance of gastric cancer 2397
E. Chandanos and J. Lagergren

Clinical Oncology

- Multimodality treatment of mesenteric desmoid tumours 2404
M.M. Bertagnolli, J.A. Morgan, C.D.M. Fletcher, C.P. Raut, P. Dileo, R.R. Gill, G.D. Demetri and S. George
- A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer 2411
I.I. Na, T.H. Lee, D.H. Choe, G.J. Cheon, C.H. Kim, J.S. Koh, H. Baek, B.-Y. Ryoo, S.H. Yang and J.C. Lee
- An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer 2418
G. van Andel, A. Bottomley, S.D. Fosså, F. Efficace, C. Coens, S. Guerif, H. Kynaston, P. Gontero, G. Thalmann, A. Akdas, S. D'Haese and N.K. Aaronson, on behalf of the EORTC Genito-Urinary Tract Cancer Group and the EORTC Quality of Life Group
- Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer 2425
Y. Liu, H. Yu, C. Zhang, Y. Cheng, L. Hu, X. Meng and Y. Zhao
- Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group 2433
M. Schlemmer, P. Reichardt, J. Verweij, J.T. Hartmann, I. Judson, A. Thyss, P.C.W. Hogendoorn, S. Marreaud, M. Van Glabbeke and J.Y. Blay
- Evidence of autonomic dysregulation in otherwise healthy cancer caregivers: A possible link with health hazard 2437
D. Lucini, V. Cannone, M. Malacarne, D. Bruno, S. Beltrami, P. Pizzinelli, E. Piazza, G. Di Fede and M. Pagani
- Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours 2444
A.-R. Hanauske, C. Endler, T. Graefe, J. Fleeth, J. von Scheel, F.E. Lüdtkke, S. Müller-Hagen, H. Depenbrock, U. Ohnmacht and C. Bolling

Paediatric Oncology

- A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG) 2453
G. Vassal, F. Giammarile, M. Brooks, B. Georger, D. Couanet, J. Michon, E. Stockdale, M. Schell, A. Geoffray, J.-C. Gentet, F. Pichon, H. Rubie, L. Cisar, S. Assadourian and B. Morland
- First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: Results of the Coopral-97 study 2461
C. Domenech, M. Mercier, E. Plouvier, M. Puraveau, P. Bordigoni, G. Michel, Y. Benoit, G. Leverger, A. Baruchel and Y. Bertrand

Epidemiology and Cancer Prevention

- Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study 2470
L.G. Capelle, A.C. de Vries, C.W.N. Looman, M.K. Casparie, H. Boot, G.A. Meijer and E.J. Kuipers
- Endometrioid and clear cell ovarian cancers – A comparative analysis of risk factors 2477
C.M. Nagle, C.M. Olsen, P.M. Webb, S.J. Jordan, D.C. Whiteman and A.C. Green, for the Australian Cancer Study group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group

Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up A. Schlesinger-Raab, U. Treiber, D. Zaak, D. Hölzel and J. Engel	2485
Experimental Oncology	
p16 methylation does not affect protein expression in cervical carcinogenesis K. Nehls, S. Vinokurova, D. Schmidt, F. Kommoss, M. Reuschenbach, F. Kisseljov, J. Eienkel, M. von Knebel Doeberitz and N. Wentzensen	2496
Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone P. Zwolak, P. Jasinski, K. Terai, N.J. Gallus, M.E. Ericson, D.R. Clohisy and A.Z. Dudek	2506
Expression of integrin-linked kinase and its binding partners in chondrosarcoma: Association with prognostic significance D.J. Papachristou, V. Gkretsi, U.N.M. Rao, G.I. Papachristou, O.A. Papaefthymiou, E.K. Basdra, C. Wu and A.G. Papavassiliou	2518
Bone morphogenetic proteins induce expression of metalloproteinases in melanoma cells and fibroblasts T. Rothhammer, S. Braig and A.-K. Bosserhoff	2526
Calendar of Forthcoming Meetings	I

NUMBER 17

News	2535
Editorial Comment	
Needle core biopsy for screen detected breast lesions: Time to raise the bar? H.M. Verkooijen	2540
Short Communication	
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) C.M.L. van Herpen, L.D. Locati, J. Buter, J. Thomas, J. Bogaerts, D. Lacombe, P. de Mulder, A. Awada, L. Licitra, J. Bernier and J.B. Vermorken	2542
Current Perspective	
Hyperthermia adds to chemotherapy R.D. Issels	2546
Reviews	
Inoperable colorectal liver metastases: A declining entity? G. Garcea, S.L. Ong and G.J. Maddern	2555
Religion and reduced cancer risk – What is the explanation? A review A. Hoff, C.T. Johannessen-Henry, L. Ross, N.C. Hvidt and C. Johansen	2573
Clinical Oncology	
Audit of performance of needle core biopsy diagnoses of screen detected breast lesions M.E. El-Sayed, E.A. Rakha, J. Reed, A. HS Lee, A.J. Evans and I.O. Ellis	2580
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’ S. Collette, L. Collette, T. Budiharto, J.-C. Horiot, P.M. Poortmans, H. Struikmans, W. Van den Bogaert, A. Fourquet, J.J. Jager, W. Hoogenraad, R.-P. Mueller, J. Kurtz, D.A.L. Morgan, J.-B. Dubois, E. Salamon, R. Mirimanoff, M. Bolla, M. Van der Hulst, C.C. Wárlám-Rodenhuis and H. Bartelink, EORTC Radiation Oncology Group	2587
‘No risk, no fun’: Challenges for the oncology phase I clinical trial time-performance J. Verweij	2600

Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study L. Bodnar, G. Wcislo, A. Gasowska-Bodnar, A. Synowiec, K. Szarlej-Wcislo and C. Szczylik	2608
The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine S. Lopatriello, D. Amoroso, S. Donati, O. Alabiso, L. Forti, A. Fornasiero, A. Smergo, A. Lalli, C. Iacono, A. Lucenti, L. D'Alonzo and C. Negrini	2615
Maximising recruitment into randomised controlled trials: The role of multidisciplinary cancer teams A.G.K. McNair, C.T.P. Choh, C. Metcalfe, D. Littlejohns, C.P. Barham, A. Hollowood, S.J. Falk and J.M. Blazeby	2623
Knowledge and understanding among cancer patients consenting to participate in clinical trials M. Bergenmar, C. Molin, N. Wilking and Y. Brandberg	2627
Paediatric Oncology	
Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma C. Perfumo, S. Parodi, K. Mazzocco, R. Defferrari, A. Inga, R. Haupt, G. Fronza and G.P. Tonini	2634
Magnetic resonance spectroscopy in the assessment of pilocytic astrocytomas L.M. Harris, N.P. Davies, L. MacPherson, S. Lateef, K. Natarajan, M.-A. Brundler, S. Sgouros, M.W. English, T.N. Arvanitis, R.G. Grundy and A.C. Peet	2640
Epidemiology and Cancer Prevention	
Interleukin-10 -1082 promoter polymorphism associated with gastric cancer among Asians Y. Zhou, N. Li, W. Zhuang, G.-J. Liu, T.-X. Wu, X. Yao, L. Du, M.-L. Wei and X.-T. Wu	2648
Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men S.C. Larsson, S.-O. Andersson, J.-E. Johansson and A. Wolk	2655
How to interpret the relative survival ratios of cancer patients A. Pokhrel and T. Hakulinen	2661
Experimental Oncology	
HMGAI protein is a novel target of the ATM kinase F. Pentimalli, D. Palmieri, R. Pacelli, C. Garbi, R. Cesari, E. Martin, G.M. Pierantoni, P. Chieffi, C.M. Croce, V. Costanzo, M. Fedele and A. Fusco	2668
Wnt1 overexpression promotes tumour progression in non-small cell lung cancer C.-L. Huang, D. Liu, S. Ishikawa, T. Nakashima, N. Nakashima, H. Yokomise, K. Kadota and M. Ueno	2680
Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions N. Ramírez, E. Bandrés, A. Navarro, A. Pons, S. Jansa, I. Moreno, F. Martínez-Rodenas, R. Zárate, N. Bitarte, M. Monzó and J. García-Foncillas	2689
Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer C. Rossi, A. Di Lena, R. La Sorda, R. Lattanzio, L. Antolini, C. Patassini, M. Piantelli and S. Alberti	2696
Calendar of Forthcoming Meetings	I

NUMBER 18

Advances in Translational Research in Breast Cancer: Bridge to Future Therapies
Guest Editors: C. Sotiriou and L. Pusztai

Editorial

Advances in translational research in breast cancer; a bridge to future therapies <i>C. Sotiriou and L. Pusztai</i>	2705
Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utility <i>R. Simon</i>	2707
Gene expression predictors in breast cancer: Current status, limitations and perspectives <i>C. Desmedt, E. Ruiz-García and F. André</i>	2714
The direct molecular analysis of metastatic precursor cells in breast cancer: A chance for a better understanding of metastasis and for personalised medicine <i>C.A. Klein</i>	2721
Micrometastatic disease in breast cancer: Clinical implications <i>M. Ignatiadis, V. Georgoulas and D. Mavroudis</i>	2726
Proteomics: New technologies and clinical applications <i>M. Latterich, M. Abramovitz and B. Leyland-Jones</i>	2737
Converting evidence to practice: A guide for the clinical application of MRI for the screening and management of breast cancer <i>J. Zakhireh, R. Gomez and L. Esserman</i>	2742
MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer <i>M.V. Iorio, P. Casalini, E. Tagliabue, S. Ménard and C.M. Croce</i>	2753
Molecular characterisation of the tumour microenvironment in breast cancer <i>M. Hu and K. Polyak</i>	2760
Targeting tumour hypoxia in breast cancer <i>M. Milani and A.L. Harris</i>	2766
Can genetic testing guide treatment in breast cancer? <i>A. Tutt and A. Ashworth</i>	2774
Targeted therapies in breast cancer: Where are we now? <i>S. Di Cosimo and J. Baselga</i>	2781
Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime? <i>A. Di Leo, L. Biganzoli, W. Claudino, S. Licitra, M. Pestrin and D. Larsimont</i>	2791
What is triple-negative breast cancer? <i>W.J. Irvin Jr. and L.A. Carey</i>	2799
Her2-positive breast cancer: Herceptin and beyond <i>W. Dean-Colomb and F.J. Esteva</i>	2806
Molecular analysis of hormone receptor positive (luminal) breast cancers – What have we learnt? <i>S. Loi</i>	2813

SUPPLEMENT 1

Systemic treatment of patients with gastrointestinal stromal tumor: current status and future opportunities

SUPPLEMENT 2

Appropriate chemotherapy – optimal results
Highlights from a teaching course under the auspices of EORTC
Edited by David Cameron and Matti Aapro

Nice, France

10–11 November 2006

SUPPLEMENT 3

5th International Conference – Cancer Prevention 2008 – Advances in Molecular and Clinical Aspects of Cancer Prevention

SUPPLEMENT 4

Breast Cancer and Ovarian Cancer: State of the Art Treatment Approaches

SUPPLEMENT 5

Evolving options and future challenges for targeted therapies in ErbB2 (HER2)-positive breast cancer.
Based on the GlaxoSmithKline-sponsored satellite symposium, held at ECCO 14

24th September 2007

Barcelona, Spain

SUPPLEMENT 6

VEGF inhibition: changing the face of breast cancer management

SUPPLEMENT 7

The 6th European breast cancer conference - EBCC-6
Abstract book

Edited by E. Rutgers, I. Kössler, M. Rosselli Del Turco, H. Bonnefoi and M. Untch

Berlin, Germany

15–19 April 2008

SUPPLEMENT 8

Proceedings of the Rome Forum on the Treatment of Breast Cancer

SUPPLEMENT 9

20th Meeting of the European Association for Cancer Research

5–8 July 2008

Lyon, France

Integrative Molecular Cancer Epidemiology – An IARC-EACR-AACR-ECNIS Symposium

3–5 July 2008

Proceedings Book

SUPPLEMENT 10

Traditional and Novel Taxanes for the Treatment of Breast Cancer: Pitfalls, Progress, and Potential
Proceedings

of a satellite symposium held at the European Breast Cancer Conference in April 2008

SUPPLEMENT 11

Focal Liver Lesions – The Key Role of Contrast-Enhanced UltraSound (CEUS) Modality for Diagnosis and Early Assessment of
Treatment Efficacy

SUPPLEMENT 12

20th EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
Programme and Abstract Book

Geneva, Switzerland

21–24 October 2008

SUPPLEMENT 13

Current and future approaches to palliative colorectal cancer care

SUPPLEMENT 14

Appropriate Patterns in Oncology 10th GOIM National Congress

22–25 June 2008

Naples, Italy

Edited by Giuseppe Colucci, Giacomo Cartenì and Evaristo Maiello